Forensic Regulatory Interventions
Elite technical diagnostics to preempt major deficiencies and secure commercial clearance for high-stakes assets.
Pre-Assessment Intake Mock Review
This intervention executes a rigorous structural and administrative diagnostic designed to guarantee your dossier breaches the Health Authority's initial intake window without friction. We mandate a strict alignment of your submission against regional ACTD or CTD formatting parameters, ensuring absolute baseline compliance before the regulator ever touches the file.
Our assessment encompasses an exhaustive verification of all legal documents, coupled with a precise formatting and navigation check to validate searchable PDFs and pagination in accordance with stringent e-submission rules. Furthermore, we execute a preliminary regulatory audit of labeling components and perform a high-level module inventory mapping. The ultimate objective is to aggressively secure your place in the evaluation queue and strictly preempt any risk of immediate administrative rejection.
Small Molecule Technical Diagnostic and Mock Review
This tier constitutes an exhaustive, deep-dive mock review of your core scientific foundation for standard small molecule applications. We initiate this intervention through a forensic validation of critical certifications against distinct product parameters. Our quality evaluation aggressively targets the CMC architecture, ensuring absolute alignment of product information across the proposed composition, batch manufacturing records, and commercial-scale parameters. We rigorously interrogate the manufacturing process, in-process controls, and the justification of specifications, alongside a severe review of all test procedures, analytical method validations (AMV), and stability data profiles to intercept critical data integrity flaws.
Crucially, this tier includes an uncompromising technical audit of Bioequivalence methodologies. We forensically evaluate in-vitro to in-vivo correlations, statistical robustness, mandatory baseline corrections, and specific analyte justifications, holding your data to the exact, stringent standards of ASEAN, ICH, and targeted regional bioequivalence guidelines.
Complex Assets and Biologicals Governance Mock Review
This tier is engineered for high-acuity assets demanding extreme technical scrutiny, including Biologicals, Biosimilars, Vaccines, and Monitored Release products targeted for high-barrier jurisdictions. Our forensic mock review penetrates the extreme complexity of biological dossiers, executing a deep-dive evaluation of the entire CMC matrix—from initial cell line development and characterization through all upstream and downstream manufacturing processes. For biosimilars, we mandate strict scrutiny of the comparability exercises to ensure undeniable analytical and functional equivalence before the dossier is finalized.
Furthermore, we perform an in-depth clinical diagnostic, zeroing in on the pivotal clinical studies directly linked to the proposed indication to validate efficacy endpoints, immunogenicity, and safety profiles against stringent regulatory expectations. Coupled with a rigorous diagnostic of cold chain integrity, temperature excursions, and complex degradation pathways, we architect a precision-engineered, scientifically impenetrable market pathway for your most difficult therapeutics.
We execute uncompromising technical governance across the entire pharmaceutical lifecycle, engineering definitive pathways for new product registrations, complex post-approval variations, and critical deficiency rescues. Operating exclusively from the vantage point of a former Health Authority Lead Assessor, we do not provide administrative checklists. Instead, we subject your raw commercial data to a hostile, regulator-grade forensic mock review.
Anchored strictly in core ICH, ASEAN, and specific regional regulatory frameworks, our interventions proactively identify data integrity flaws and structural vulnerabilities. By anticipating agency queries before they are issued, we neutralize scientific gaps and re-architect your dossier into a scientifically defensible narrative built to withstand the most intense regulatory scrutiny.
FAQs
What is required to initiate a technical review?
We make the onboarding process entirely frictionless. Upon initial contact, we will immediately provide a standard Mutual Non-Disclosure Agreement (MNDA) for your approval. Once executed, we will provision a dedicated, encrypted data room where your team can safely drop the CTD, eCTD, or ACTD submission files.
Do you guarantee Health Authority approval?
While no consultancy guarantees automatic approval, our diagnostics are conducted from the perspective of a former National Health Authority Lead Assessor. We leverage a documented track record of successfully resolving complex health authority queries.
Who exactly will be auditing my submission?
Your dossier is not handed off to junior staff. It is directly assessed by a Principal Consultant with over 13 years of regulatory experience, specializing in the critical assessment of new drug applications ranging from generics to complex biologicals.
Can you assist if we already received a Notice of Deficiencies?
Yes. We specialize in the technical remediation and re-authoring of deficient third-party dossiers (CMC and Clinical). We author high-impact, science-based responses to translate complex technical data into regulator-friendly submissions.
Which regulatory jurisdictions and regions are within your core expertise?
Our primary operational footprint covers the Philippines and the greater ASEAN bloc, alongside extensive, hands-on assessment experience with GCC (Gulf Cooperation Council) and EMA (European Medicines Agency) regulations. Because our audits are strictly anchored in core ICH guidelines, our technical evaluations translate seamlessly across these high-scrutiny jurisdictions.
What payment methods are accepted?
For engagements within the Philippines, we accept direct corporate bank transfers as well as secure digital disbursements via GCash and Maya. For international clients, bespoke wire instructions and cross-border payment options will be provided alongside your formal corporate invoice prior to the commencement of the review.
Strategic Regulatory Intelligence and forensic technical audits for high-acuity pharmaceutical assets.
Data Integrity Notice:
All submissions are transmitted via encrypted channels and bound by institutional MNDA protocols. Regustat operates under strict professional governance for pharmaceutical compliance.
© 2026 Regustat. All rights reserved.